David Oxlade

David has over 40 years’ experience in the health care field, including more than 15 years as Chairman, CEO and Non-Executive Director of European and US listed and private companies.

Currently Chairman of TranScrip Partners LLP, Kirkstall Ltd and Oxford Cancer Biomarkers Ltd, David has previously served on the Boards of a number of other health care companies, and worked at senior executive level in the USA and Asia with companies including Syva Company in California, AstraZeneca PLC and Boehringer Mannheim GmbH, now part of the Roche group.

He served on the UK’s Bioscience Leadership Council and EuropaBio’s Emerging Enterprise Council and is an Honorary Fellow of Brunel University.